Why Indian Drug Makers Challenge Global Patents
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
Category : Search result: affordable generic drugs
Generic Drugs as Good as Brands, Cost Far Less: Study
A citizen-funded study finds generic medicines, including Jan Aushadhi, match quality of expensive brands. Experts urge trust in affordable options for better treatment adherence. #Healthcare #India
Novo Nordisk: Wegovy Price Cut to Boost India Obesity Therapy 5-7x
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Generic Semaglutide to Create Rs 50,000 Cr Market
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Generic Semaglutide to Create Rs 50bn+ Revenue Opportunity
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Semaglutide Patent Expiry Creates Rs 50,000 Cr Opportunity
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
Weight-loss drugs poised for takeoff, cancer care expands in 2026
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
Indian Pharma Firms Eye Licensing Deals for Obesity Drugs
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
India's 2025 Health Shift: Prevention, Generics & Digital Tools
From preventive screenings to affordable generics, 2025 reshaped India's health priorities. Discover the key trends that made wellness a daily habit and what it means for 2026.
Bengaluru engineer arrested for making drugs at home
A Bengaluru software engineer was arrested for allegedly manufacturing synthetic drugs like MDMA in a makeshift home laboratory. Police seized drugs worth lakhs and equipment. Read the shocking details.
DCA Raids Quack's Clinic, Seizes Illegal Drugs Worth ₹15,011
Drugs Control Administration officials raided an unlicensed clinic in Karimnagar, seizing illegal steroids and antibiotics. The crackdown highlights the public health risks of unauthorized drug sales. Read more.
India's Weight-Loss Drug Market to Grow 10x by 2030
Explore the social and economic impact of GLP-1 drugs like Ozempic & Mounjaro in India. A ₹1,000 crore market is poised for massive growth. Share your thoughts.
Zota Health Raises ₹350 Crore, Signs Dhoni & Shetty
Zota Health Care secures ₹350 crore from investors via QIP to fund expansion. MS Dhoni & Suniel Shetty join as brand ambassadors. Aim to open 5000+ generic pharmacy stores by 2029.
Ajanta Pharma & Biocon Partner for Generic Weight Loss Drug
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
GLP-1 Drugs Show Benefits Beyond Weight Loss
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
India Pharma Targets $500B, Innovation Hub by 2047
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Lack of Drug Inspectors Hampers Action on Spurious Drugs
A severe shortage of drug inspectors is hampering enforcement against spurious and adulterated medicines in India. Officials admit the staffing crisis is a major hurdle. Read more on the critical public health issue.
Govt's Data Exclusivity Push May Hit Cheap Generic Drugs
The Indian government is considering data exclusivity for pharma, a move that could delay cheap generic drugs, impact India's global edge, and affect medicine access. Read the full analysis.
Himachal Leads Nation in Substandard Drugs: 49 Fail
Himachal Pradesh reports the highest number of substandard drug samples in India. 49 samples failed quality tests, raising serious concerns about public health and pharmaceutical regulation.
Jan Aushadhi Kendra rules changed: 500-meter gap enforced
The Indian government mandates a 500-meter distance between Jan Aushadhi Kendras in major cities to protect store viability and ensure access to affordable generic medicines. Learn about the new policy's impact.
Supreme Court to Hear Bikram Majithia's Bail Plea on July 15
The Supreme Court has agreed to hear SAD leader Bikram Singh Majithia's plea for bail in a drugs case. The hearing is scheduled for July 15. Read the latest legal developments.
Bangladesh Beats India to Export Weight-Loss Drugs to Emerging Markets
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Karnataka Passes Key Amendment to Drugs and Cosmetics Act
Karnataka Assembly passes the Drugs and Cosmetics (Amendment) Bill, 2024, enhancing penalties for spurious drug manufacturers and regulating online pharmacy sales. Learn the key changes.
Karnataka to appeal HC order on Jan Aushadi Kendras closure
Karnataka Health Minister Dinesh Gundu Rao announces state will appeal HC order quashing closure of Jan Aushadi Kendras in govt hospitals. Read the full story.
Shark Tank's Mittal on Ozempic Launch & 2026 Pharma Shift
Shark Tank India's Anupam Mittal comments on Ozempic's India launch, its ₹8,800/month price, and the 2026 patent expiry that could 5x the market. Read his take on fitness shortcuts vs. discipline.
Delhi seals shop, seizes 204 drug samples in Bhagirath Palace raid
Delhi's Drugs Control department sealed a shop & collected 204 samples from 27 wholesale dealers in a major drive against illegal drug trade. Health Minister vows zero tolerance for spurious medicines.
Court Rejects Ozempic Patent Extension, Boosts Generic Drug Access
Delhi High Court rejects Novo Nordisk's patent plea on semaglutide (Ozempic/Wegovy), preventing 'evergreening'. A win for affordable generics in India, but raises concerns over non-clinical misuse of weight-loss drugs. Read more.
Dr Reddy's Wins Delhi HC Nod to Export Semaglutide
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
Himachal Schools & Police Launch Anti-Drug Sports Drive
Himachal Pradesh schools partner with police in innovative sports initiative to combat drug abuse among youth. Learn how education and sports create positive alternatives.
Indian-origin man jailed in UK for £4M heroin smuggling
Rajesh Bakshi and accomplice Jon-Paul Clark sentenced for attempting to smuggle 40kg heroin into UK. NCA investigation reveals international drug trafficking network.
Page 1 of 4